Research has highlighted the benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in managing blood glucose and reducing weight in individuals with type 2 diabetes (T2D) and/or obesity.1 However, current trends on how these drugs are prescribed across indications and subpopulations remain unknown. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.